Labtec and GSK finalize license agreement
Labtec and Glaxo Smith Kline finalize licence agreement on a new topical patch for the treatment of cold sores
In a recently finalized license agreement, the Consumer Healthcare division of GlaxoSmithKline acquired the exclusive marketing rights for a new topical patch for the treatment of cold sores from Labtec GmbH, the transdermal and topical patch specialist based in Langenfeld, Germany. The agreement designates Labtec as the exclusive manufacturer.
PRESS RELEASE
The product is based on Labtec's proprietary LabiPatch platform technology. It is especially suitable for easy, convenient application of patches on the delicate surface of the lip. Encompassing patches with and without active ingredients, the LabiPatch technology is designed to promote the healing process by maintaining a moist and optimal healing environment.
"In GlaxoSmithKline we have found an outstanding development and marketing partner for our innovative patch technology," says Ingo Lehrke, Managing Director of Labtec. "We are confident that this partnership will deliver improved therapy options for a multitude of patients suffering from cold sores."
About Labtec GmbH
Founded in 1990 as an independent start-up company, Labtec has quickly become one of the leading drug delivery development companies in the transdermal and topical patch arena, later also leading the market with fast dissolving oral films in Europe. In 2008, Labtec became a wholly owned subsidiary of tesa SE and today represents tesa's pharmaceutical business. In 2009, Labtec started operations at a new 3,000 m² GMP manufacturing site for patches and oral films. tesa and Labtec are members of the Beiersdorf group of companies.